Shares of Epocrates EPOC are bid lower in the after-hours following the release of the company's Q4 earnings results. Currently, shares are bid $8.20, at $10.25; they ended the regular session lower by 0.10%, at $10.25.
Epocrates reported Q4 EPS of ($0.27) on revenues of $29.7 million. Q4 adjusted EBITDA was $3.1 million, while gross margin came in at 60.6%.
The company said it is exploring strategic alternatives for its electronic health records offering.
The company sees 2012 revenues in the range of $105-115 million.
Epocrates, Inc., is a provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in